| __timestamp | BeiGene, Ltd. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 1244910 |
| Thursday, January 1, 2015 | 7311000 | 5029636 |
| Friday, January 1, 2016 | 20097000 | 4846776 |
| Sunday, January 1, 2017 | 62602000 | 5329003 |
| Monday, January 1, 2018 | 195385000 | 7121000 |
| Tuesday, January 1, 2019 | 388249000 | 9128000 |
| Wednesday, January 1, 2020 | 600176000 | 10731000 |
| Friday, January 1, 2021 | 990123000 | 10701000 |
| Saturday, January 1, 2022 | 1277852000 | 16121000 |
| Sunday, January 1, 2023 | 1504501000 | 37021000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, operational costs can be a significant indicator of a company's growth and strategic direction. BeiGene, Ltd. and Viking Therapeutics, Inc., two prominent players in the industry, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. BeiGene's SG&A expenses have skyrocketed by over 21,500% during this period, reflecting its aggressive expansion and investment in global operations. In contrast, Viking Therapeutics has maintained a more conservative growth, with its SG&A expenses increasing by approximately 2,900%. This stark difference highlights BeiGene's rapid scaling strategy compared to Viking's more measured approach. As the biotech landscape continues to evolve, these financial strategies will play a crucial role in shaping the future trajectories of these companies.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and BeiGene, Ltd.
Operational Costs Compared: SG&A Analysis of argenx SE and Viking Therapeutics, Inc.
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Xencor, Inc.